Prevacid patent upheld

Share this article:
A federal judge has upheld a Takeda Pharmaceutical and Abbott Laboratories patent for the drugmakers' jointly marketed heartburn drug Prevacid.

The ruling "will ease investor concerns regarding the pending split of the TAP joint venture between Abbott and Takeda," analyst Lawrence Keusch of Goldman Sachs said in an investor note. “The ruling should also keep generic competition at bay and allow Abbott to collect royalties on an intact Prevacid franchise prior to the patent expiration in 2009.”

US District Judge Sue Robinson, in Wilmington, Delaware, ruled a patent on Prevcid is both valid and enforceable.

Generics drugmaker Teva, which sought to market a copycat version of the drug, has pledged to appeal.

Prevacid is made by TAP Pharmaceutical Products, a joint-venture between Takeda and Abbott.  Last month, the companies agreed to split the venture, with Takeda getting Prevacid. Analysts said in published reports that the court decision will ensure that agreement goes as planned since a loss would have required a renegotiation between Abbott and Takeda.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?